Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $508,900.00 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sarepta Therapeutics Stock Down 2.5 %

SRPT opened at $132.58 on Thursday. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The firm has a 50 day moving average price of $125.37 and a 200-day moving average price of $111.22. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89. The stock has a market capitalization of $12.53 billion, a price-to-earnings ratio of 1,205.27 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the previous year, the company earned ($1.44) earnings per share. The firm’s quarterly revenue was up 63.1% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.23 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Securities Inc. bought a new position in Sarepta Therapeutics in the fourth quarter worth approximately $26,000. Mather Group LLC. bought a new position in Sarepta Therapeutics in the first quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares during the period. Montag A & Associates Inc. bought a new position in Sarepta Therapeutics in the third quarter worth approximately $30,000. Finally, Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several research reports. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Evercore ISI upped their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. Royal Bank of Canada upped their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Citigroup upped their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Finally, UBS Group upped their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $160.60.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.